| Title |
Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
|
|---|---|
| Published in |
Biologics: Targets & Therapy, March 2008
|
| DOI | 10.2147/btt.s1877 |
| Pubmed ID | |
| Authors |
Archana Monie, Chien-Fu Hung, Richard Roden, T-C Wu |
| Abstract |
Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix() is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 259 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| India | 1 | <1% |
| Mauritius | 1 | <1% |
| Unknown | 255 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 55 | 21% |
| Student > Master | 49 | 19% |
| Student > Ph. D. Student | 35 | 14% |
| Researcher | 22 | 8% |
| Student > Postgraduate | 16 | 6% |
| Other | 31 | 12% |
| Unknown | 51 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 62 | 24% |
| Agricultural and Biological Sciences | 43 | 17% |
| Medicine and Dentistry | 37 | 14% |
| Immunology and Microbiology | 15 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 4% |
| Other | 30 | 12% |
| Unknown | 61 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2016.
All research outputs
#7,356,550
of 25,374,917 outputs
Outputs from Biologics: Targets & Therapy
#94
of 284 outputs
Outputs of similar age
#30,188
of 95,559 outputs
Outputs of similar age from Biologics: Targets & Therapy
#6
of 10 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,559 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.